# reload+after+2024-01-23 15:46:43.447258
address1§200 Powder Mill Road
city§Wilmington
state§DE
zip§19803
country§United States
phone§302 467 1280
website§https://preludetx.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma. The company is also developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 2 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.
fullTimeEmployees§122
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Krishna  Vaddi D.V.M., Ph.D.', 'age': 57, 'title': 'Founder, CEO & Director', 'yearBorn': 1966, 'fiscalYear': 2022, 'totalPay': 805908, 'exercisedValue': 0, 'unexercisedValue': 3838080}, {'maxAge': 1, 'name': 'Dr. Edna  Huang M.D.', 'age': 50, 'title': 'President & Chief Medical Officer', 'yearBorn': 1973, 'fiscalYear': 2022, 'totalPay': 563555, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Peggy A. Scherle Ph.D.', 'age': 62, 'title': 'Chief Scientific Officer', 'yearBorn': 1961, 'fiscalYear': 2022, 'totalPay': 868617, 'exercisedValue': 0, 'unexercisedValue': 436567}, {'maxAge': 1, 'name': 'Mr. Laurent  Chardonnet M.B.A.', 'age': 58, 'title': 'Chief Financial Officer', 'yearBorn': 1965, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Aimee  Crombie Ph.D.', 'title': 'Senior VP and Head of Strategic Planning & Operations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Madhu  Pudipeddi Ph.D.', 'title': 'Senior Vice President of Technical Operations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Lindsey  Trickett', 'title': 'Vice President of Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Bryant David Lim J.D.', 'age': 52, 'title': 'Chief Legal Officer & Corporate Secretary', 'yearBorn': 1971, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Michele  Porreca M.B.A.', 'title': 'Chief People Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Andrew P. Combs Ph.D.', 'age': 57, 'title': 'Executive VP & Head of Chemistry', 'yearBorn': 1966, 'fiscalYear': 2022, 'totalPay': 562461, 'exercisedValue': 0, 'unexercisedValue': 399432}]
auditRisk§2
boardRisk§5
compensationRisk§9
shareHolderRightsRisk§10
overallRisk§9
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§1.384
currency§USD
dateShortInterest§1702598400
forwardEps§-1.28
pegRatio§-0.06
exchange§NMS
quoteType§EQUITY
shortName§Prelude Therapeutics Incorporat
longName§Prelude Therapeutics Incorporated
firstTradeDateEpochUtc§1601040600
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§b4d5f445-4c0f-32e5-9fdb-a86b330519d9
gmtOffSetMilliseconds§-18000000
targetHighPrice§10.0
targetLowPrice§3.0
targetMeanPrice§5.38
targetMedianPrice§4.25
recommendationMean§3.0
recommendationKey§hold
numberOfAnalystOpinions§4
quickRatio§13.645
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
